Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Goodwill & Intangibles (2022 - 2026)

Axsome Therapeutics' Goodwill & Intangibles history spans 5 years, with the latest figure at $51.0 million for Q1 2026.

  • On a quarterly basis, Goodwill & Intangibles fell 32.73% to $51.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $51.0 million, a 32.73% decrease, with the full-year FY2025 number at $75.8 million, up 28.78% from a year prior.
  • Goodwill & Intangibles hit $51.0 million in Q1 2026 for Axsome Therapeutics, down from $75.8 million in the prior quarter.
  • Over the last five years, Goodwill & Intangibles for AXSM hit a ceiling of $75.8 million in Q3 2025 and a floor of $51.0 million in Q1 2026.
  • Historically, Goodwill & Intangibles has averaged $69.7 million across 5 years, with a median of $72.8 million in 2022.
  • Biggest five-year swings in Goodwill & Intangibles: rose 28.78% in 2025 and later crashed 32.73% in 2026.
  • Tracing AXSM's Goodwill & Intangibles over 5 years: stood at $70.0 million in 2022, then fell by 6.7% to $65.3 million in 2023, then dropped by 9.79% to $58.9 million in 2024, then increased by 28.78% to $75.8 million in 2025, then crashed by 32.77% to $51.0 million in 2026.
  • Business Quant data shows Goodwill & Intangibles for AXSM at $51.0 million in Q1 2026, $75.8 million in Q4 2025, and $75.8 million in Q3 2025.